^
    Back
    Association details:
    Biomarker:PDGFRA D842V
    Cancer:Gastrointestinal Stromal Tumor
    Drug:crenolanib (ARO-002) (FLT3 inhibitor, PDGFR α inhibitor, PDGFR β inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

    Excerpt:
    ...Histologically or cytologically-confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene as determined by central laboratory testing 2....
    Trial ID:
    NCT02847429
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

    Excerpt:
    ...To determine the response rate of patients with advanced D842V mutant GIST, when treated with Crenolanib (CP-868,596). ...
    Trial ID:
    NCT01243346
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.

    Excerpt:
    We here report a phase I/II study evaluating safety, PKs, and antitumor efficacy of crenolanib in advanced GIST with PDGFRA D842V....2/16 pts achieved a PR while 3/16 pts achieved SD; clinical benefit rate was 31% (5/16 pts)
    Trial ID:
    NCT01243346